Received Jun 30, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
received 1st dose on 31-MAY-2025 and 2nd dose on 01-JUN-2025; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a 31-year-old female patient who received HAB (Twinrix) for prophylaxis. Concomitant products included Hepatitis a vaccine inact, Hepatitis b vaccine rHBsAg (yeast) (Twinrix). On 01-JUN-2025, the patient received the 2nd dose of Twinrix. On 01-JUN-2025, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too short (Verbatim: received 1st dose on 31-MAY-2025 and 2nd dose on 01-JUN-2025). The outcome of the drug dose administration interval too short was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 23-JUN-2025 The pharmacist reported that the patient received their first dose of Twinrix in May 2025 and the second dose in June 2025 and wanted to know when the third dose should be given. They did not want to provide more data and declined to receive follow-up. The reporter was conflictive and rude during the call, stating that they did not see why providing more data for the case would help them get an answer. The patient received 2nd dose of Twinrix vaccine earlier than the recommended interval, which led to shortening of the vaccination.